![]() | |
Clinical data | |
---|---|
AHFS/ Drugs.com | Monograph |
Routes of administration | IV only |
Drug class | Vasodilatation [1] |
Chemical and physical data | |
Formula | C143H244N50O42S4 |
Molar mass | 3464.07 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Nesiritide, sold under the brand name Natrecor among others, is a medication developed to treat acute decompensated congestive heart failure. [1] Evidence; however, has failed to show benefit. [2] [1] It is given into a vein. [1]
Common side effects include low blood pressure, headache, nausea, and back pain. [1] Other side effects may include allergic reactions, kidney problems, and death. [1] It is a recombinant form of B-type natriuretic peptide, which results in vasodilatation. [1]
Nesiritide was approved for medical use in the United States in 2001. [1] In the United States it costs about 1,100 USD per 1.5 mg vial. [3] Commercial sale; however, has been discontinued as of 2021. [4]
![]() | |
Clinical data | |
---|---|
AHFS/ Drugs.com | Monograph |
Routes of administration | IV only |
Drug class | Vasodilatation [1] |
Chemical and physical data | |
Formula | C143H244N50O42S4 |
Molar mass | 3464.07 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Nesiritide, sold under the brand name Natrecor among others, is a medication developed to treat acute decompensated congestive heart failure. [1] Evidence; however, has failed to show benefit. [2] [1] It is given into a vein. [1]
Common side effects include low blood pressure, headache, nausea, and back pain. [1] Other side effects may include allergic reactions, kidney problems, and death. [1] It is a recombinant form of B-type natriuretic peptide, which results in vasodilatation. [1]
Nesiritide was approved for medical use in the United States in 2001. [1] In the United States it costs about 1,100 USD per 1.5 mg vial. [3] Commercial sale; however, has been discontinued as of 2021. [4]